Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Declines By 23.4%

Posted by Joseph Casey on Mar 6th, 2025

Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Free Report) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 934,300 shares, a drop of 23.4% from the January 31st total of 1,220,000 shares. Approximately 1.3% of the shares of the company are short sold. Based on an average daily trading volume, of 690,700 shares, the short-interest ratio is currently 1.4 days.

Institutional Trading of Tiziana Life Sciences

Several institutional investors have recently modified their holdings of the company. Sanctuary Advisors LLC bought a new position in Tiziana Life Sciences in the third quarter worth $864,000. Zhang Financial LLC lifted its holdings in shares of Tiziana Life Sciences by 34.3% during the 4th quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock worth $65,000 after acquiring an additional 23,800 shares during the period. Geode Capital Management LLC boosted its position in shares of Tiziana Life Sciences by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock valued at $171,000 after acquiring an additional 27,041 shares in the last quarter. Finally, Bison Wealth LLC acquired a new stake in shares of Tiziana Life Sciences during the 4th quarter valued at about $30,000.

Tiziana Life Sciences Price Performance

TLSA stock opened at $1.36 on Thursday. Tiziana Life Sciences has a twelve month low of $0.41 and a twelve month high of $1.74. The business’s 50-day simple moving average is $0.79 and its 200 day simple moving average is $0.90.

About Tiziana Life Sciences

(Get Free Report)

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.